Small Molecule Drug Discovery, Bristol Myers Squibb, Princeton, NJ 08543, USA.
Translational Medicine, Bristol Myers Squibb, Princeton, NJ 08543, USA.
Bioanalysis. 2020 Oct;12(20):1469-1481. doi: 10.4155/bio-2020-0198. Epub 2020 Oct 2.
Discovery proteomics research has made significant progress in the past several years; however, the number of protein biomarkers deployed in clinical practice remains rather limited. There are several scientific and procedural gaps between discovery proteomics research and clinical implementation, which have contributed to poor biomarker validity and few clinical applications. The complexity and low throughput of proteomics approaches have added additional barriers for biomarker assay translation to clinical applications. Recently, targeted proteomics have become a powerful tool to bridge the biomarker discovery to clinical validation. In this perspective, we discuss the challenges and strategies in proteomics research from a clinical perspective, and propose several recommendations for discovery proteomics research to accelerate protein biomarker discovery and translation for future clinical applications.
在过去的几年中，发现蛋白质组学研究取得了重大进展；然而，在临床实践中应用的蛋白质生物标志物的数量仍然相当有限。发现蛋白质组学研究与临床实施之间存在一些科学和程序上的差距，这导致生物标志物的有效性较差，临床应用也较少。蛋白质组学方法的复杂性和低通量增加了将生物标志物测定转化为临床应用的额外障碍。最近，靶向蛋白质组学已成为将生物标志物发现与临床验证联系起来的有力工具。从临床角度来看，在本文中我们讨论了蛋白质组学研究中的挑战和策略，并提出了一些针对发现蛋白质组学研究的建议，以加速蛋白质生物标志物的发现和转化，用于未来的临床应用。
